ClinicalTrials.gg
Sign In

Drug

Garetatug rezetecan clinical trials

studies test it
10
open now
8
in phase 3
1
first study started
2021

Keep track of what changes. Save the garetatug rezetecan studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.

Watch these studies

How studies write it

Studies that test it under each name

Name

SHR-A1904
6
SHR-A1904 for Injection
2

Combined with it in one product

SHR-A1904; Adebrelimab
1
SHR-A1904; CAPOX; Adebrelimab
1

Studies by the year they started

10 studies that test it; most in 2026 (3)

Studies that test garetatug rezetecan, by start year
YearStudies
20212
20221
20242
20252
20263

By phase

A phase 1/2 study counts in both.

Phase 1
4
Phase 2
6
Phase 3
1

What it is tested for

Each study’s main condition, where its own words name it.

Stomach Neoplasms
2
Biliary Tract Neoplasms
1
Pancreatic Neoplasms
1

Who runs them

Industry 7 · Other 3

Shanghai Hengrui Pharmaceutical Co., Ltd. (4) · Suzhou Suncadia Biopharmaceuticals Co., Ltd. (2) · Peking University Cancer Hospital & Institute (1) · Beijing GoBroad Hospital (1) · China Medical University, China (1) · Jiangsu HengRui Medicine Co., Ltd. (1)

Often tested with

Tested in the same studies.

Adebrelimab (2) · Trastuzumab rezetecan (2) · Trastuzumab (1) · Apatinib (1) · Tegafur (1) · Gimeracil (1) · Oxonic Acid (1) · Capecitabine (1)

Studies

Open first, then newest update. How each study uses garetatug rezetecan is read from its arms, and is right about nine times in ten.

Testing it · 10

Given in every arm · 1 — garetatug rezetecan is usual care beside what is tested

Codes

What other systems call garetatug rezetecan · ClinicalTrials.gg INT016551

  • UNII (FDA) FD5J5RLD4EGARETATUG REZETECANOne source FDA
  • NCI Thesaurus C181025Garetatug RezetecanOne source FDA

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.